论文部分内容阅读
目的通过观察治疗前后急性心力衰竭患者心功能的改善情况,评价应用重组人B型利钠肽(rhBNP)治疗急性心力衰竭的临床疗效。方法选择急性心力衰竭患者62例按随机数字表法分为rhBNP治疗组32例和对照组(硝酸甘油组)30例,观察2组患者治疗前后临床症状、体征的改善情况,及用药前后心输出量(CO)、心脏指数(CI)、每搏输出量(SV)和外周血管阻力(SVR)的变化,以评价rhBNP对心功能的影响。结果 rhBNP治疗组患者的临床症状及体征改善总有效率为100%,对照组的总有效率66.7%,rhBNP治疗组总有效率显著优于对照组(χ2=14.472,P=0.000);2组患者治疗后与治疗前比较,CO、CI、SV均显著增加(P均<0.05),SVR明显降低(P均<0.05),且rhBNP治疗组治疗后CO、CI、SV及SVR较对照组治疗后改善更加显著(P均<0.05)。结论应用rhBNP治疗急性心力衰竭患者的心功能有明显改善,临床疗效显著。
Objective To evaluate the clinical efficacy of recombinant human B-type natriuretic peptide (rhBNP) in the treatment of acute heart failure by observing the improvement of cardiac function in patients with acute heart failure before and after treatment. Methods Sixty-two patients with acute heart failure were randomly divided into rhBNP treatment group (n = 32) and control group (n = 30). The clinical symptoms and signs of two groups were observed before and after treatment, and the cardiac output (CO), cardiac index (CI), stroke volume (SV) and peripheral vascular resistance (SVR) changes in order to evaluate the impact of rhBNP on cardiac function. Results The total effective rate of clinical symptoms and signs in rhBNP treatment group was 100%, while the total effective rate in control group was 66.7%. The total effective rate of rhBNP treatment group was significantly better than that of control group (χ2 = 14.472, P = 0.000) The levels of CO, CI, SV in the rhBNP group were significantly higher than those in the control group after treatment (all P <0.05) and SVR (all P <0.05) After improvement more significant (P all <0.05). Conclusion The application of rhBNP in patients with acute heart failure has significantly improved cardiac function, clinical efficacy significantly.